Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Non-Hodgkin lymphoma]

M Ogawa1

  • 1Aichi Cancer Center, Nagoya, Japan.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|August 1, 1996
PubMed
Summary
This summary is machine-generated.

Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy showed equal effectiveness and lower toxicity compared to other regimens. Despite its benefits, ongoing research explores more potent treatments for improved efficacy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Present status and clinical therapy of pancreatic diseases].

Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine·1992
Same author

Reptilian viruses: adenovirus-like agent isolated from royal python (Python regius).

Zentralblatt fur Veterinarmedizin. Reihe B. Journal of veterinary medicine. Series B·1992
Same author

Specific stimulation by estradiol of tissue-type plasminogen activator production in 7,12-dimethylbenz[a]anthracene-induced rat mammary tumor cells.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme·1992
Same author

Magnocellular neurosecretory neurons with ferritin-like immunoreactivity in the hypothalamic supraoptic and paraventricular nuclei of the rat.

Brain research·1992
Same author

Changes in IL-6, IL-8, C-reactive protein and pancreatic secretory trypsin inhibitor after transcatheter arterial chemo-embolization therapy for hepato-cellular carcinoma.

Cytokine·1992
Same author

Light microscopic immunohistochemical analysis of the distribution of group II phospholipase A2 in human digestive organs.

The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society·1992
Same journal

[A Case of Pulmonary Epithelioid Hemangioendothelioma Associated with Multiple Cancers].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Long-Term Survival in Three Cases with Pulmonary Metastases from Colorectal Cancer Given Low-Dose S-1 Under a Regimen Combining a Carbohydrate-Restricted Ketogenic Diet, Metformin, Vitamin D, Eicosapentaenoic Acid, and Other Complementary Therapies].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Preventive Effect of Saline Eye Wash for Eye Symptoms Due to High-Dose and Intermediate-Dose Cytarabine Therapy].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Examination of Factors Affecting the Efficacy of Naldemedine Tosilate Tablets for Opioid-Induced Constipation].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Recent Advances in the Treatment of HER2-Altered Solid Tumors].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[BRAF-Mutant Solid Tumor].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
See all related articles

Area of Science:

  • Oncology
  • Clinical Trials
  • Pharmacology

Context:

  • Prospective randomized trial by SWOG evaluated chemotherapy regimens.
  • CHOP regimen demonstrated comparable efficacy to newer combinations.
  • CHOP exhibited the lowest toxic death rate among studied treatments.

Purpose:

  • To compare the efficacy and toxicity of the CHOP regimen against second and third-generation chemotherapy combinations.
  • To review ongoing research for enhanced chemotherapy regimens with higher dose intensity and stem cell support.

Summary:

  • The CHOP regimen demonstrated equivalent efficacy to newer combination therapies in a SWOG trial.
  • CHOP was associated with the lowest toxic death rate, supporting its role as a standard treatment.
  • Despite CHOP's established efficacy, research continues to investigate regimens offering higher dose intensity and improved outcomes.

Related Experiment Videos

Impact:

  • CHOP remains a benchmark treatment due to its favorable efficacy and safety profile.
  • Findings support the continued use of CHOP while acknowledging the need for further therapeutic advancements.
  • The review of novel regimens highlights the evolving landscape of cancer treatment strategies.